Nykode Therapeutics AS (NYKD.OL)

NOK 3.19

(-4.61%)

Total Liabilities Summary of Nykode Therapeutics AS

  • Nykode Therapeutics AS's latest annual total liabilities in 2023 was 375 Million USD , down -40.94% from previous year.
  • Nykode Therapeutics AS's latest quarterly total liabilities in 2024 Q2 was 27.79 Million USD , down -16.19% from previous quarter.
  • Nykode Therapeutics AS reported annual total liabilities of 634.97 Million USD in 2022, up 0.71% from previous year.
  • Nykode Therapeutics AS reported annual total liabilities of 630.51 Million USD in 2021, up 43.89% from previous year.
  • Nykode Therapeutics AS reported quarterly total liabilities of 359.85 Million USD for 2024 Q1, down -10.17% from previous quarter.
  • Nykode Therapeutics AS reported quarterly total liabilities of 375 Million USD for 2023 FY, down -40.94% from previous quarter.

Annual Total Liabilities Chart of Nykode Therapeutics AS (2023 - 2016)

Historical Annual Total Liabilities of Nykode Therapeutics AS (2023 - 2016)

Year Total Liabilities Total Liabilities Growth
2023 375 Million USD -40.94%
2022 634.97 Million USD 0.71%
2021 630.51 Million USD 43.89%
2020 438.18 Million USD 766.47%
2019 50.57 Million NOK 281.21%
2018 13.26 Million NOK 21.29%
2017 10.93 Million NOK -37.88%
2016 17.6 Million NOK 0.0%

Peer Total Liabilities Comparison of Nykode Therapeutics AS

Name Total Liabilities Total Liabilities Difference
Arctic Bioscience AS 41.69 Million NOK -799.425%
Aqua Bio Technology ASA 15.72 Million NOK -2285.089%
ArcticZymes Technologies ASA 30.02 Million NOK -1148.949%
BerGenBio ASA 46.85 Million NOK -700.293%
Hofseth BioCare ASA 348.97 Million NOK -7.459%
PCI Biotech Holding ASA 5 Million NOK -7388.206%
Thor Medical ASA 58.91 Million NOK -536.58%
Ultimovacs ASA 69.64 Million NOK -438.435%